ResMed shareholders also sleep well at night

August 6, 2018

Sleep device maker ResMed this morning reported a 13% increase in revenue for the year ended 30 June 2018 together with a 27% increase in operating income. Chief Executive, Mick Farrell, was reported as saying that “we closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth, driven by geographically balanced results across our entire portfolio of offerings”.  The company is well positioned for fiscal year 2019.

Resmed is one of Morgan Wealth’s core shareholdings and has produced a return of 47% for the 12 months ended 31 July 2018.

Our Top Recommendations
Total returns on capital growth and dividends for 12 months ended 31 July 2018
Afterpay Touch
357.42%
Lovisa Holdings
175.33%
Altium Limited
136.00%
Relance Worldwide
85.64%
Nextdc Limited
75.43%
Xero Ltd
72.09%
CSL Limited
57.56%
Macquarie Group
49.21%
Resmed Inc
47.17%
Orocobre Limited
44.97%
ASX200 Accum Index (comparison)
14.59%